Navigation Links
Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
Date:4/4/2008

as bypass surgery to reopen the arteries. The Zilver PTX trials will determine whether the combination of the stent and paclitaxel will keep arteries open over time.

About Peripheral Artery Disease (PAD)

Peripheral Artery Disease (PAD) affects blood vessels that lead from the heart to other areas of the body, such as the legs, feet and kidneys. When the blood vessels become blocked due to the build-up of fatty deposits, blood circulation is restricted. Untreated, PAD results in pain when walking and can lead to gangrene and amputation.

Note on Forward Looking Statements

Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimate," "continue," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions,
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Angiotech to participate in Credit Suisse Global Leveraged Finance Conference
2. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
3. Angiotech to participate in Lehman Brothers Healthcare Conference
4. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
5. Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
6. Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
7. Angiotech announces results for the fourth quarter ended December 31, 2007
8. Angiotech to participate in Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
10. Angiotech and Symphony Medical Announce Licensing Agreement
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 2013 was a ... Brain State Technologies®. They saw continued independent research led ... who were awarded a $1 million grant from the ... “Brain and Behavior” a peer reviewed journal, Amy Grant ...
(Date:1/15/2014)... 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today announced ... a leading Russian pharmaceutical company, to develop and commercialize ... Federation , Turkey and ... a novel antibiotic for the treatment of bacterial infections ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Calif., Feb. 29 Kosan Biosciences,Incorporated (Nasdaq: ... Kosan,s,Senior Vice President and Chief Financial Officer, will ... Healthcare Conference in,New York at the W Hotel ... EST. A live,webcast of the presentation can be ...
... MannKind,Corporation (Nasdaq: MNKD ) will release its ... at 7:00 a.m. ET., Management of the Company ... financial results, clinical progress and other Company,developments at 9:00 ... the,Company will be its Chairman and Chief Executive Officer, ...
... DEERFIELD, Ill., Feb. 28 Baxter International,Inc. announced ... voluntary,recall of all remaining lots and doses of ... heparin flush products., The company initially recalled ... January 17, 2008 as a precautionary measure due ...
Cached Biology Technology:Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference 2MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008 2Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products 2Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products 3
(Date:4/17/2014)... peppers. Information about archaeological remains of ancient chili peppers ... of words for chili peppers in ancient dialects helped ... the value of multi-proxy data analysis. Their results are ... presented in a special feature issue of the ... plant and animal domestication edited by Dolores Piperno, staff ...
(Date:4/17/2014)... NJ. April 16, 2014. Kessler Foundation has been ... million from the Department of Defense Spinal Cord ... principal investigator for the randomized, double-blinded, controlled, multi-site ... bone and muscle strength after spinal cord injury. ... & Engineering Research at Kessler Foundation. Two additional ...
(Date:4/17/2014)... Luca Razzari of the nergie Matriaux Tlcommunications Research ... the John R. Evans Leaders Fund of the ... of state-of-the-art biotech and nanophotonics equipment. To this ... Ministre de l,Enseignement suprieur, de la Recherche, de ... new laboratories will help us develop new approaches ...
Breaking Biology News(10 mins):Chickens to chili peppers 2Chickens to chili peppers 3Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2New state-of-the-art biotech and nanotech equipment for INRS 2
... few extra treats this holiday season? Soon, your cell ... exercise routine and keep the pounds off over winter ... keep track. Researchers at the University of Washington ... dubbed UbiFit and UbiGreen, to automatically track workouts and ...
... PITTSBURGHTwo groups of researchers at Carnegie Mellon University,s Robotics ... grants from the U.S. Department of Agriculture (USDA) to ... and one is for orange growers, but both are ... The systems use sensors on autonomous robotic vehicles ...
... new compounds created by a University of Central Florida ... Associate Professor James Turkson,s compounds disrupt the formation ... mice. The compounds, S3I-201 and S3I-M2001, break up ... no negative side effects so far. "The compounds ...
Cached Biology News:Track your fitness, environmental impact with new cell phone applications 2Track your fitness, environmental impact with new cell phone applications 3Carnegie Mellon developing automated systems to enable precision farming of apples, oranges 2Carnegie Mellon developing automated systems to enable precision farming of apples, oranges 32 new compounds show promise for eliminating breast cancer tumors 2
...
... Antibody Modification Services ,,GenScript ... antibody labeling and antibody fragmentation. Labeling ... signals for visualization and quantitation of ... it is preferable to use only ...
Attoglow Western Blot Enhancing Kit contains Millennium Enhancer which can significantly boost Western blot signals, and is compatible with other enhancing mechanisms to achieve multiplied enhancing ...
Immunogen: Synthetic peptide: S(399) P W S E L E F Q F P D D K D P V W E F(418) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: